CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Upcoming FDA decision · January 18, 2027

ET-105 PDUFA date: FDA decision expected January 18, 2027

The FDA is expected to decide on ET-105 from Eton Pharmaceuticals, Inc. in adult refractory gastroesophageal reflux disease (rGERD) by the PDUFA target action date of January 18, 2027. For adult refractory gastroesophageal reflux disease (rGERD). NDA filing. Extracted from SEC filing: 8-K

A PDUFA date is the FDA's target deadline to complete its review of a drug application — approval, a complete response letter (CRL), or an extension are all possible. What is a PDUFA date? This page is research information, not financial advice.

Source: sec.gov · Data checked November 17, 2026. How we check dates. Confirm dates against the company's or the FDA's announcement before acting.

Get an email when this FDA date moves or the decision lands

Track Eton Pharmaceuticals, Inc. (ETON) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

January 18
Target action date
NDA
Stage
Detected
Date confidence
—
FDA designations

Questions about this FDA decision

When is the PDUFA date for ET-105?
The FDA's PDUFA target action date for ET-105 is January 18, 2027. The FDA can act before that date, and the review can be extended.
What is ET-105 being reviewed for?
The application under FDA review covers adult refractory gastroesophageal reflux disease (rGERD).
Which company is developing ET-105?
Eton Pharmaceuticals, Inc. (ETON).
What can happen on a PDUFA date?
The FDA approves the application, issues a complete response letter (CRL) listing what must be fixed before approval, or extends the review (typically by three months after a major amendment).